BRIACELL THERAPEUTICS CORP (BCTX) Stock News

USA - NASDAQ:BCTX - CA1079303071 - Common Stock

13.34 USD

-0.08 (-0.6%)

Last: 10/28/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BCTX Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Chartmill - Mentions: GM IBIO SPWR ADAP ...

News Image

Traders are paying attention to the gapping stocks in Tuesday's session.

7 days ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

8 days ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

8 days ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

9 days ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

16 days ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

26 days ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

2 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

2 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

2 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Announces Proposed Effective Date of Share Consolidation

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Announces Proposed Effective Date of Share Consolidation

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

3 months ago - By: BriaCell Therapeutics Corp.; BriaPro Therapeutics Corp. - Mentions: BCT.CA

BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Therapeutics Announces Closing of $15 million Public Offering

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

5 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

5 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

5 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

5 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

5 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell CEO Letter to Shareholders

6 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

6 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

6 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development